CryoPort, Inc. (NASDAQ:CYRX) Director Ramkumar Mandalam Sells 13,321 Shares

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) Director Ramkumar Mandalam sold 13,321 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $7.01, for a total value of $93,380.21. Following the transaction, the director now owns 73,056 shares in the company, valued at approximately $512,122.56. The trade was a 15.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ramkumar Mandalam also recently made the following trade(s):

• On Friday, June 13th, Ramkumar Mandalam sold 624 shares of CryoPort stock. The shares were sold at an average price of $6.80, for a total value of $4,243.20.
• On Thursday, June 12th, Ramkumar Mandalam sold 1,895 shares of CryoPort stock. The stock was sold at an average price of $7.01, for a total transaction of $13,283.95.
• On Wednesday, June 11th, Ramkumar Mandalam sold 8,193 shares of CryoPort stock. The shares were sold at an average price of $7.06, for a total transaction of $57,842.58.
• On Monday, June 9th, Ramkumar Mandalam sold 5,622 shares of CryoPort stock. The stock was sold at an average price of $7.06, for a total transaction of $39,691.32.

CryoPort Stock Up 2.1%

Shares of NASDAQ:CYRX traded up $0.15 during trading on Thursday, hitting $7.29. The stock had a trading volume of 299,675 shares, compared to its average volume of 518,676. The company has a market capitalization of $365.52 million, a PE ratio of -3.12 and a beta of 1.85. The company has a quick ratio of 5.24, a current ratio of 5.56 and a debt-to-equity ratio of 0.51. The firm's fifty day moving average is $6.29 and its 200 day moving average is $6.70. CryoPort, Inc. has a 12 month low of $4.58 and a 12 month high of $9.78.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. The business had revenue of $41.04 million during the quarter, compared to the consensus estimate of $56.19 million. CryoPort had a negative return on equity of 11.03% and a negative net margin of 50.15%. Analysts anticipate that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Franklin Resources Inc. boosted its stake in CryoPort by 0.4% during the fourth quarter. Franklin Resources Inc. now owns 387,131 shares of the company's stock worth $3,012,000 after acquiring an additional 1,512 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of CryoPort by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock valued at $492,000 after purchasing an additional 1,764 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its position in shares of CryoPort by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after purchasing an additional 2,120 shares in the last quarter. Sierra Summit Advisors LLC boosted its position in shares of CryoPort by 5.0% in the 1st quarter. Sierra Summit Advisors LLC now owns 45,060 shares of the company's stock worth $274,000 after purchasing an additional 2,150 shares in the last quarter. Finally, Nebula Research & Development LLC grew its stake in shares of CryoPort by 21.6% in the 4th quarter. Nebula Research & Development LLC now owns 12,442 shares of the company's stock worth $97,000 after buying an additional 2,207 shares during the last quarter. 92.90% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on CYRX shares. Morgan Stanley dropped their target price on shares of CryoPort from $8.00 to $7.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price target on shares of CryoPort in a research report on Thursday, May 8th. UBS Group lifted their price objective on CryoPort from $10.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday, April 1st. Roth Mkm reissued a "buy" rating and set a $15.00 target price on shares of CryoPort in a research note on Tuesday, April 1st. Finally, Guggenheim restated a "buy" rating and set a $10.00 target price on shares of CryoPort in a report on Wednesday, April 16th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $11.00.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.